Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-10 4:52 pm Purchase | 2023-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 5,995,928 10.800% | 3,116,103 (+108.20%) | Filing History |
| 2024-01-09 4:45 pm Purchase | 2024-01-05 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 5,831,171 9.990% | 1,138,567 (+24.26%) | Filing History |
| 2023-06-05 4:10 pm Sale | 2023-06-01 | 13D | Kymera Therapeutics, Inc. KYMR | VERTEX PHARMACEUTICALS INC VRTX | 0 0.000% | -3,151,121 (Position Closed) | Filing History |
| 2023-02-14 4:28 pm Sale | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Atlas Venture Fund X L.P. | 5,066,925 9.200% | -696,087 (-12.08%) | Filing History |
| 2023-02-14 4:27 pm Purchase | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Redmile Group, LLC | 2,673,837 4.900% | 86,107 (+3.33%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BAKER BROS. ADVISORS LP | 2,879,825 5.200% | 2,879,825 (New Position) | Filing History |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 4,379,159 8.000% | -845,527 (-16.18%) | Filing History |
| 2023-02-14 09:37 am Purchase | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Avoro Capital Advisors LLC | 3,850,000 7.000% | 3,850,000 (New Position) | Filing History |
| 2023-02-09 11:25 am Purchase | 2022-12-30 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 3,660,307 6.670% | 703,133 (+23.78%) | Filing History |
| 2023-02-08 2:16 pm Purchase | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | STATE STREET CORP STT | 2,846,221 5.190% | 2,846,221 (New Position) | Filing History |
| 2023-02-06 3:02 pm Purchase | 2022-12-30 | 13G | Kymera Therapeutics, Inc. KYMR | Wellington Management Group LLP | 4,591,089 8.370% | 1,896,275 (+70.37%) | Filing History |
| 2023-02-01 4:54 pm Sale | 2022-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | BlackRock Inc. BLK | 3,334,901 6.100% | -62,639 (-1.84%) | Filing History |
| 2022-08-23 4:45 pm Purchase | 2022-08-22 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 4,692,604 8.600% | 553,846 (+13.38%) | Filing History |
| 2022-07-11 2:10 pm Purchase | 2022-06-30 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 5,224,686 10.100% | 1,674,158 (+47.15%) | Filing History |
| 2022-06-01 5:00 pm Purchase | 2022-05-27 | 13D | Kymera Therapeutics, Inc. KYMR | BIOTECHNOLOGY VALUE FUND L P | 4,138,758 8.000% | 552,100 (+15.39%) | Filing History |
| 2022-02-14 5:07 pm Sale | 2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Redmile Group, LLC | 2,587,730 5.000% | -132,759 (-4.88%) | Filing History |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | T. Rowe Price Associates, Inc. | 3,550,528 6.900% | 3,550,528 (New Position) | Filing History |
| 2022-02-11 5:09 pm Sale | 2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | Atlas Venture Fund X L.P. | 5,763,012 11.200% | -2,185,970 (-27.50%) | Filing History |
| 2022-02-10 08:22 am Purchase | 2021-12-31 | 13G | Kymera Therapeutics, Inc. KYMR | The Vanguard Group | 2,957,174 5.750% | 2,957,174 (New Position) | Filing History |
| 2022-02-09 09:22 am Sale | 2022-02-08 | 13G | Kymera Therapeutics, Inc. KYMR | FMR LLC | 2,347,527 4.568% | -94,533 (-3.87%) | Filing History |